Avoid common mistakes on your manuscript.
Correction to: Neurol Ther (2019) 8:461–475 https://doi.org/10.1007/s40120-019-0146-z
Figures 1a, 1b and 3 were published incorrectly in the original version. The corrected images are given as follows.
Fig. 1 Kaplan–Meier estimates of time to 6 m-CDI (a) and 6 m-CDI+ (b) in young adult patients and the overall analysis population from pooled FREEDOMS/FREEDOMS II studies. The Cox regression model was adjusted for sex, age, baseline EDSS and number of relapses in the 2 years prior to the study. Subjects with baseline EDSS score < 2.0 were excluded for 6m-CDI. Subjects with baseline EDSS score ≤ 2.0 were excluded for 6m-CDI+ 6m-CDI 6-month confirmed disability improvement, 6m-CDI+ 6-month confirmed disability improvement-plus, CI confidence interval, EDSS Expanded Disability Status Scale, FTY fingolimod, HR hazard ratio
Fig. 3 Time to EDSS ≥ 4.0 in young adult patients and the overall analysis population from pooled FREEDOMS/FREEDOMS II studies. The Cox regression model was adjusted for sex, age, baseline EDSS and number of relapses in the 2 years prior to the study. Subjects with baseline EDSS score ≥ 4.0 were excluded. CI confidence interval, EDSS Expanded Disability Status Scale, FTY fingolimod, HR hazard ratio
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ghezzi, A., Chitnis, T., K-Laflamme, A. et al. Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials. Neurol Ther 9, 193–195 (2020). https://doi.org/10.1007/s40120-020-00178-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40120-020-00178-4